Markmanadvisors.com / Investors & Patents
Domain overview in Investors & Patents niche. Based on relevant links and pages only.
| markmanadvisors.com rank 139 |
| Number of domains linking to markmanadvisors.com 1 | semantic flow 0.04 |
| Number of links to markmanadvisors.com 1 | semantic flow 0.04 |
| Number of domains linked from markmanadvisors.com 15 | semantic flow 1.73 |
| Number of links from markmanadvisors.com 23 | semantic flow 1.73 |
Popular pages pointing to markmanadvisors.com
Pages with highest topical PageRank pointing to domain.
| url / atext / target url | |
|---|---|
http://www.litigationalpha.com/  markman advisors ↳http://www.markmanadvisors.com/ | www.litigationalpha.com |
Popular pages from markmanadvisors.com
On-topic pages from domain with highest topical PageRank.
| title / url |  | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Blog u2014 Markman Advisors https://www.markmanadvisors.com/blog/?tag=immunity | 0.28 | 1 | 26 | 16 | 0 | 0 | 0 | 0 | |
| Can Celgene protect Revlimid® from Dr. Reddy's generic? u2014 Markman Advisors https://www.markmanadvisors.com/blog/2018/1/30/can-celgene-protect-revlimid-from-dr-reddys | 0.28 | 1 | 27 | 18 | 1 | 1 | 0 | 0 | |
| When do biosimilars launch at risk? u2014 Markman Advisors https://www.markmanadvisors.com/blog/2018/1/25/why-do-biosimilars-launch-at-risk | 0.28 | 1 | 66 | 27 | 3 | 2 | 0 | 0 |
Domains with most semantic flow to markmanadvisors.com
Relevant domains with most links to selected domain.
| domain | | | |
|---|---|---|---|
| http://litigationalpha.com/ | 1 | 0.04 | litigationalpha.com |
Domains with most semantic flow from markmanadvisors.com
Relevant domains with most links from selected domain.
Most linked pages from markmanadvisors.com
Pages from domain with most relevant inbound links.
| url | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://www.markmanadvisors.com/s/Markman-Advisors-Newsletter-March-2016.pdf | 1 | 0.21 | 0.92 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://www.markmanadvisors.com/monetization | 1 | 0.16 | 0.93 | 0.07 | 1 | yes | 14 | 6 | 0 | 0 | 0 | 0 | |
| https://www.markmanadvisors.com/monetization/ | 1 | 0.16 | 0.98 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://www.markmanadvisors.com/valuation | 1 | 0.16 | 0.93 | 0.07 | 1 | yes | 15 | 7 | 1 | 1 | 0 | 0 | |
| https://www.markmanadvisors.com/consulting | 1 | 0.16 | 0.93 | 0.06 | 1 | yes | 16 | 8 | 1 | 1 | 0 | 0 | |
| https://www.markmanadvisors.com/consulting/ | 1 | 0.16 | 0.98 | 0.06 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://www.markmanadvisors.com/valuation/ | 1 | 0.16 | 0.97 | 0.06 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://www.markmanadvisors.com/contact/ | 1 | 0.16 | 0.95 | 0.06 | 1 | yes | 14 | 6 | 0 | 0 | 0 | 0 | |
| https://www.markmanadvisors.com/blog/ | 1 | 0.16 | 0.8 | 0.05 | 1 | yes | 175 | 115 | 2 | 2 | 0 | 0 | |
| https://www.markmanadvisors.com/news/ | 1 | 0.16 | 0.6 | 0.04 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 |
Hubs from markmanadvisors.com
Pages from domain with most likely on-topic outgoing links.
| url | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://www.markmanadvisors.com/blog/ | 109 | 0.16 | 0.8 | 8.27 | 1 | yes | 175 | 115 | 2 | 2 | 0 | 0 | |
| https://www.markmanadvisors.com/ | 9 | 0.15 | 0.93 | 0.55 | 1 | yes | 14 | 9 | 0 | 0 | 0 | 0 | |
| https://www.markmanadvisors.com/blog/2017/12/12/can-you-patent-blockchain | 3 | 0.15 | 0.99 | 0.21 | 1 | yes | 32 | 21 | 5 | 5 | 0 | 0 | |
| https://www.markmanadvisors.com/blog/2017/12/4/what-do-the-amici-say-about-the-allergan-st | 3 | 0.15 | 0.98 | 0.2 | 1 | yes | 31 | 10 | 2 | 2 | 0 | 0 | |
| https://www.markmanadvisors.com/consulting | 2 | 0.16 | 0.93 | 0.14 | 1 | yes | 16 | 8 | 1 | 1 | 0 | 0 | |
| https://www.markmanadvisors.com/blog/2018/2/2/will-amgens-latest-neulasta-patent-loss-agai | 1 | 0.15 | 0.99 | 0.07 | 1 | yes | 36 | 21 | 0 | 0 | 0 | 0 | |
| https://www.markmanadvisors.com/valuation | 1 | 0.16 | 0.93 | 0.07 | 1 | yes | 15 | 7 | 1 | 1 | 0 | 0 | |
| https://www.markmanadvisors.com/blog/2018/1/11/can-coherus-invalidate-amgens-enbrel-patent | 1 | 0.15 | 0.97 | 0.07 | 1 | yes | 33 | 11 | 2 | 2 | 0 | 0 | |
| https://www.markmanadvisors.com/blog/2018/1/24/can-coherus-invalidate-amgens-enbrel-patent | 1 | 0.15 | 0.96 | 0.07 | 1 | yes | 29 | 9 | 0 | 0 | 0 | 0 | |
| https://www.markmanadvisors.com/blog/2018/1/5/does-sandoz-have-a-double-patenting-defense- | 1 | 0.15 | 0.98 | 0.06 | 1 | yes | 27 | 8 | 1 | 1 | 0 | 0 |